|
nasdaq:acrs
|
10404193
|
May 5th, 2024 12:00AM
|
Aclaris Therapeutics, Inc.
|
7.0K
|
67.00
|
Open
|
|
May 4th, 2024 10:39PM
|
May 4th, 2024 10:39PM
|
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.
|
Open
|
|
Open
|
640 Lee Rd
|
Wayne
|
Pennsylvania
|
US
|
19087
|
|
Aclaris Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:acrs
|
10404193
|
May 4th, 2024 12:00AM
|
Aclaris Therapeutics, Inc.
|
7.0K
|
67.00
|
Open
|
|
May 3rd, 2024 10:33PM
|
May 4th, 2024 06:15PM
|
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.
|
Open
|
|
Open
|
640 Lee Rd
|
Wayne
|
Pennsylvania
|
US
|
19087
|
|
Aclaris Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:acrs
|
10404193
|
May 3rd, 2024 12:00AM
|
Aclaris Therapeutics, Inc.
|
7.0K
|
68.00
|
Open
|
|
May 2nd, 2024 10:29PM
|
May 3rd, 2024 01:59PM
|
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.
|
Open
|
|
Open
|
640 Lee Rd
|
Wayne
|
Pennsylvania
|
US
|
19087
|
|
Aclaris Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:acrs
|
10404193
|
May 2nd, 2024 12:00AM
|
Aclaris Therapeutics, Inc.
|
7.0K
|
68.00
|
Open
|
|
May 1st, 2024 10:36PM
|
May 2nd, 2024 09:34AM
|
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.
|
Open
|
|
Open
|
640 Lee Rd
|
Wayne
|
Pennsylvania
|
US
|
19087
|
|
Aclaris Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:acrs
|
10404193
|
May 1st, 2024 12:00AM
|
Aclaris Therapeutics, Inc.
|
7.0K
|
68.00
|
Open
|
|
Apr 30th, 2024 11:13PM
|
May 1st, 2024 09:01AM
|
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.
|
Open
|
|
Open
|
640 Lee Rd
|
Wayne
|
Pennsylvania
|
US
|
19087
|
|
Aclaris Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:acrs
|
10404193
|
Apr 30th, 2024 12:00AM
|
Aclaris Therapeutics, Inc.
|
7.0K
|
68.00
|
Open
|
|
Apr 29th, 2024 10:41PM
|
Apr 30th, 2024 07:52AM
|
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.
|
Open
|
|
Open
|
640 Lee Rd
|
Wayne
|
Pennsylvania
|
US
|
19087
|
|
Aclaris Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:acrs
|
10404193
|
Apr 29th, 2024 12:00AM
|
Aclaris Therapeutics, Inc.
|
7.0K
|
68.00
|
Open
|
|
Apr 28th, 2024 11:20PM
|
Apr 29th, 2024 09:00AM
|
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.
|
Open
|
|
Open
|
640 Lee Rd
|
Wayne
|
Pennsylvania
|
US
|
19087
|
|
Aclaris Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:acrs
|
10404193
|
Apr 28th, 2024 12:00AM
|
Aclaris Therapeutics, Inc.
|
7.0K
|
68.00
|
Open
|
|
Apr 27th, 2024 10:38PM
|
Apr 27th, 2024 10:38PM
|
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.
|
Open
|
|
Open
|
640 Lee Rd
|
Wayne
|
Pennsylvania
|
US
|
19087
|
|
Aclaris Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:acrs
|
10404193
|
Apr 27th, 2024 12:00AM
|
Aclaris Therapeutics, Inc.
|
7.0K
|
68.00
|
Open
|
|
Apr 26th, 2024 10:30PM
|
Apr 26th, 2024 10:30PM
|
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.
|
Open
|
|
Open
|
640 Lee Rd
|
Wayne
|
Pennsylvania
|
US
|
19087
|
|
Aclaris Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:acrs
|
10404193
|
Apr 26th, 2024 12:00AM
|
Aclaris Therapeutics, Inc.
|
7.0K
|
70.00
|
Open
|
|
Apr 25th, 2024 10:37PM
|
Apr 26th, 2024 07:57AM
|
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.
|
Open
|
|
Open
|
640 Lee Rd
|
Wayne
|
Pennsylvania
|
US
|
19087
|
|
Aclaris Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|